Negative Effects of Hyperglycemia in ELBW Preterm Infants
Hyperglycemia (>8 mmol/L or 145 mg/dL) in extremely low birth weight preterm infants is associated with increased mortality and morbidity, and should be actively avoided. 1
Key Adverse Outcomes
Mortality
- Severe hyperglycemia (≥180 mg/dL) during the first week of life is strongly associated with death, with an adjusted odds ratio of 4.68 (95% CI 1.82-12.03) 2
- Early severe hyperglycemia (first 3 days) increases odds of death or late-onset infection by 5-fold (OR 5.07,95% CI 1.06-24.3) 3
- Persistent severe hyperglycemia (first week) shows similar risk elevation (OR 6.26) 3
Retinopathy of Prematurity (ROP)
- Hyperglycemia is an independent risk factor for severe ROP requiring intervention 4
- After propensity score matching, severe ROP occurs in 21.6% of hyperglycemic infants versus 6.4% in normoglycemic infants (OR 4.0,95% CI 1.0-15.5) 5
- The association persists even after adjusting for gestational age and birth weight 4
Neurodevelopmental Impairment
- Hyperglycemia (>15 mmol/L or 270 mg/dL) is independently associated with abnormal neurodevelopmental outcomes at 18 months 6
- Developmental quotient (DQ) scores are significantly lower in hyperglycemic infants (81.0 ± 19.3 vs 91.1 ± 15.3) 6
- Normal DQ rates are reduced (37% vs 75%, p<0.001) 6
- However, after adjustment for birth weight and late-onset circulatory collapse, the association with 3-year outcomes becomes non-significant, suggesting hyperglycemia may be a marker of illness severity 7
Infectious Complications
- Increased risk of late-onset sepsis (>72 hours of life) 3
- Higher rates of ventilator-associated pneumonia (IRR 6.2,95% CI 1.4-27.6) 5
- Longer duration of invasive mechanical ventilation (mean difference 10.9 days) 5
Necrotizing Enterocolitis
- Persistent severe hyperglycemia is associated with Stage II/III NEC (OR 9.49,95% CI 1.52-59.3) after adjusting for age and sex 3
Cardiovascular Effects
- Animal models demonstrate that neonatal hyperglycemia causes significant thickening of the aortic wall, suggesting potential long-term cardiovascular implications 4
- Association with late-onset circulatory collapse 7
Clinical Thresholds and Definitions
The ESPGHAN/ESPEN/ESPR/CSPEN 2018 guidelines establish clear thresholds:
- Avoid hyperglycemia >8 mmol/L (145 mg/dL) in NICU patients (Level of Evidence 2-, Grade B recommendation) 1
- Treat repetitive blood glucose >10 mmol/L (180 mg/dL) with insulin therapy after reasonable glucose infusion rate adjustment (Level of Evidence 2+, conditional recommendation) 1
Research studies use varying definitions:
- Most commonly: >10 mmol/L (180 mg/dL) 1
- Some studies: >15 mmol/L (270 mg/dL) 6, 8
- Others: >8.5 mmol/L (153 mg/dL) 4
Important Clinical Nuances
The Enhanced Parenteral Nutrition Paradox
A critical finding shows that implementation of enhanced early parenteral nutrition protocols increased both hyperglycemia prevalence (11.6% to 41.6%) and mortality (10.9% to 24.3%) 2. However, in multivariable analysis, the enhanced PN protocol itself was not predictive of mortality—rather, the resulting severe hyperglycemia was the independent risk factor. This highlights that aggressive nutritional support must be carefully balanced against hyperglycemia risk.
Parenteral Glucose Safety Threshold
Recent data identifies 7 g/kg/day as a data-driven safety threshold for parenteral glucose intake during the first week of life 9. Exceeding this threshold is independently associated with:
- Hyperglycemia (adjusted OR 5.55,95% CI 2.56-12.03)
- Hypertriglyceridemia (adjusted OR 4.36,95% CI 1.41-13.45)
The divergence in glucose intake between affected and unaffected infants appears as early as the second day of life 9.
Insulin Therapy Considerations
Insulin therapy effectively treats hyperglycemia but carries significant hypoglycemia risk 1. The guidelines emphasize:
- Use low starting doses
- Only implement after reasonable glucose infusion rate adjustment fails
- No evidence supports tight glucose control in NICU settings 1
Importantly, insulin therapy itself does not appear to independently worsen neurodevelopmental outcomes when used appropriately for hyperglycemia (OR 0.40,95% CI 0.09-1.74 for death or neurodevelopmental impairment) 8.
Common Pitfalls to Avoid
Over-aggressive early parenteral nutrition: The drive to prevent postnatal growth failure can inadvertently cause harmful hyperglycemia 2
Delayed recognition: Hyperglycemia effects are most pronounced in the first week of life, requiring vigilant early monitoring 3, 5
Inaccurate glucose measurement: Handheld glucose meters have reduced accuracy in neonates due to high hemoglobin and bilirubin levels. Blood gas analyzers with glucose modules provide the most accurate bedside measurements 1
Treating hyperglycemia as merely a marker: While hyperglycemia correlates with illness severity, it appears to have independent adverse effects on outcomes, particularly for ROP and mortality 4, 2, 3
Long-term Monitoring Recommendations
Based on the evidence, ELBW infants with neonatal hyperglycemia require enhanced surveillance for: